Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 32 EP applications Georg von Sprecher has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11732449

IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

IPC classification:
A61K 31/4375, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP12726226

SUBSTITUTED INDOLE DERIVATIVES FOR THE TREATMENT OF IMMUNOLOGICAL DISORDERS

IPC classification:
A61K 31/496, A61P 37/00, C07D 401/14, C07F 9/141
Applicant:
Novartis AG
Applicant:
Novartis Tiergesundheit AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Agent:
Emma Marie Bassinder, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12756885

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

IPC classification:
A61K 31/437, A61P 3/00, A61P 11/00, A61P 17/00, A61P 29/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12756879

COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

IPC classification:
A61K 31/437, A61P 3/00, A61P 11/00, A61P 17/00, A61P 29/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13729219

COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY

IPC classification:
A61K 31/4439, C07D 401/14, C07D 403/04, C07D 403/14, C07D 413/04, C07D 413/14, C07D 471/04, C07D 513/04
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12761655

NOVEL PYRROLO PYRIMIDINE DERIVATIVES

IPC classification:
A61K 31/519, A61P 29/00, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11723889

TREATMENT OF AUTOIMMUNE DISEASES

IPC classification:
A61K 31/00, A61K 31/137, A61K 31/661, A61P 37/06
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13707037

SALTS OF AN IP RECEPTOR AGONIST

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13705579

7,8- DIHYDROPYRIDO [3, 4 - B]PYRAZINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13705578

FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13705581

FUSED DIHYDROPYRIDO [2,3 -B]PYRAZINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13707437

FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13705582

FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

IPC classification:
A61K 31/4985, A61P 9/00, A61P 11/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12715201

PYRAZOLO PYRIMIDINE DERIVATIVES

IPC classification:
A61K 31/519, A61P 9/00, A61P 11/00, A61P 19/00, A61P 35/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13720079

CRYSTALLINE FORM OF A SUCCINATE SALT

IPC classification:
A61K 31/438, A61P 11/00, A61P 35/00, C07D 471/10
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11715325

COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC.

IPC classification:
A61K 31/17, A61K 31/198, A61K 31/661, A61K 38/10, A61P 11/00, A61P 17/00, A61P 29/00, A61P 31/00, A61P 35/00, C07C 323/60, C07K 5/04
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11796872

COMPOSITIONS AND METHODS FOR MODULATING FXR

IPC classification:
A61K 31/46, A61P 3/00, C07D 451/06, C07D 471/04, C07D 487/04
Applicant:
Novartis AG
Agent:
Simon John Kiddle, Mewburn Ellis LLP
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
The patent has been granted
EP13779364

BICYCLIC HETEROARYL CYCLOALKYLDIAMINE DERIVATIVES AS INHIBITORS OF SPLEEN TYROSINE KINASES (SYK)

IPC classification:
A61K 31/5025, A61P 11/00, A61P 29/00, A61P 35/00, A61P 37/00, C07D 471/04
Applicant:
Novartis AG
Applicant:
Novartis Tiergesundheit AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Agent:
Emma Marie Bassinder, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13801770

COMPOUNDS FOR USE IN GASTRIC COMPLICATION

IPC classification:
A61K 31/437, A61K 31/519
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13792100

SUBSTITUTED INDOLE DERIVATIVES

IPC classification:
A61K 31/496, A61P 37/00, C07D 401/14, C07F 9/6558
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14707841

IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

IPC classification:
A61K 31/4375, A61P 3/10, A61P 7/02, A61P 9/10, A61P 11/06, A61P 19/04, A61P 29/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
PATENT GRANTED
EP14708330

TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT PATIENTS

IPC classification:
A61K 31/137, A61K 31/255, A61K 31/519, A61K 31/661, A61K 31/675, A61K 31/7076, A61K 38/13, A61N 5/00, A61P 37/06
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP11757864

PYRAZINE DERIVATIVES AS ENAC BLOCKERS

IPC classification:
A61K 31/497, A61P 11/00, C07D 241/26, C07D 403/12, C07D 487/10
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11730637

TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES

IPC classification:
A61K 31/517, A61P 29/00, C07D 471/04
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11779606

DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE

IPC classification:
A61K 31/4709, A61K 31/505, A61K 31/506, A61K 31/519, A61P 27/02
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11720419

DOSAGE REGIMEN OF DIARYL SULFIDE DERIVATIVES

IPC classification:
A61K 31/145, A61P 37/08
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14821285

NOVEL AMINO PYRIMIDINE DERIVATIVES

IPC classification:
C07D 239/47, C07D 401/10, C07D 401/12, C07D 401/14, C07D 403/12, C07D 405/12
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
The patent has been granted
EP14833234

HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

IPC classification:
A61K 31/41, A61K 31/415, A61K 31/42, C07D 231/12, C07D 257/04, C07D 271/10, C07D 401/12, C07D 413/12, C07D 417/12
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP11701825

ARYL BENZYLAMINE COMPOUNDS

IPC classification:
A61K 31/196, A61K 31/397, A61K 31/40, A61K 31/4427, A61P 37/00, C07C 229/16, C07D 205/04, C07D 207/16, C07D 401/06
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15719115

POLYCYCLIC HERG ACTIVATORS

IPC classification:
A61K 31/5025, A61P 9/06, C07D 405/04, C07D 405/12
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15733899

NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS

IPC classification:
A61K 31/519, A61P 29/00, A61P 35/00, A61P 37/00, C07D 487/04
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16702985

PET IMAGING AGENTS

IPC classification:
A61B 6/00, A61B 8/00, A61K 31/422, A61K 31/44, C07B 59/00, C07D 401/12, C07D 413/12
Applicant:
Novartis AG
Agent:
Georg von Sprecher, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature